Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE versus DEXONE 0 75.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE versus DEXONE 0 75.
DEXAMETHASONE vs DEXONE 0.75
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Dexamethasone is a potent glucocorticoid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and reduce inflammation, immune response, and adrenal function.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
0.75 mg orally once daily, typically as part of a tapering regimen for anti-inflammatory or immunosuppressive effects.
None Documented
None Documented
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Terminal elimination half-life: 36-54 hours in adults with normal renal function; prolonged to 72-168 hours in severe renal impairment.
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Renal: ~65-80% as unchanged drug; Fecal: ~10-15% as metabolites; Minor biliary excretion.
Category D/X
Category C
Corticosteroid
Corticosteroid